New Immunotherapy-Chemo cocktail takes on tough lymphoma
NCT ID NCT07444710
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II bulky to IV disease will participate. The goal is to see if this combination is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab (a monoclonal antibody) combined with chemotherapy drugs (R-CHOP and R-DHAP)
- What this could lead to
- If it works, this could point toward a more effective first-line treatment for mantle cell lymphoma that combines immunotherapy with standard chemotherapy.
- What could go wrong
- This is a very early Phase I trial with only 16 participants, so safety and dosing are still being figured out. The combination may cause severe side effects like cytokine release syndrome or nerve toxicity, and it's too soon to know if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.